Workflow
EBITDA Expansion
icon
Search documents
Encompass Health Q4 Earnings Call Highlights
Yahoo Finance· 2026-02-06 23:28
Financial Performance - In Q4, revenue increased by 9.9% to $1.5 billion, and adjusted EBITDA rose by 15.9% to $335.6 million, driven by 5.3% discharge growth and a 4.1% increase in net revenue per discharge [1][5] - For the full year 2025, revenue grew by 10.5%, with EBITDA increasing by 14.9%, supported by operating leverage and disciplined expense management [3][5] - Adjusted free cash flow for the full year was $818 million, reflecting an 18.5% increase [9] Labor and Operational Efficiency - Premium labor costs decreased significantly, down more than $21 million year-over-year in 2025, with Q4 premium labor at $23.8 million, the lowest since Q1 2021 [2][5][7] - The company added approximately 300 same-store registered nurses (RNs) during 2025, contributing to improved operational efficiency [7] Capacity Expansion and Growth Strategy - Management plans to add 517 beds in 2025 through new hospitals and expansions, with ongoing investments expected to meet a growing target demographic [12] - A new 24-bed small-format hospital prototype is set to launch in 2027 as part of a hub-and-spoke strategy [13] 2026 Guidance - For 2026, management guided net revenue of $6.365–6.465 billion, adjusted EBITDA of $1.34–1.38 billion, and adjusted EPS of $5.81–6.10, with a leverage target of approximately 1.83x [4][18] Regulatory and Payer Dynamics - The company reported a 93% affirmation rate for its Alabama hospitals under the RCD model, indicating effective engagement with CMS [16] - Management expressed concerns about challenges with a national Medicare Advantage payer, which affected conversion rates despite referral growth [20]
P3 Health Partners(PIII) - 2025 Q3 - Earnings Call Transcript
2025-11-14 14:02
Financial Data and Key Metrics Changes - Capitated revenue increased by approximately 6%, with total capitated revenue for the quarter at $341.6 million, or about $982 per member per month [5][15] - Adjusted EBITDA loss for the quarter was $45.9 million, with a year-to-date adjusted EBITDA loss of $85.2 million [8][18] - The company revised its full-year adjusted EBITDA guidance to a range of -$110 million to -$95 million, reflecting current expectations [9][20] Business Line Data and Key Metrics Changes - Membership was approximately 116,000 members, aligning with expectations [8] - Medical margin for the quarter was $4.4 million, or $13 per member per month, compared to $500,000 or $1 per member per month in the prior period [16] - Year-to-date medical margin was $52.2 million, or $50 per member per month [16] Market Data and Key Metrics Changes - The normalized adjusted EBITDA loss year-to-date was approximately $70 million, providing a clearer reflection of underlying performance [8] - The operational improvement plan achieved over $100 million in EBITDA improvement year-over-year [7] Company Strategy and Development Direction - The company is focused on improving stability, strengthening operating discipline, and maturing its clinical foundation [5] - A strategic joint venture is expected to add approximately 13,000 fully accredited ACO members, enhancing profitability and cash flow [7] - The company is rationalizing its provider network to improve margin performance, exiting groups that do not align clinically or economically [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the core operating model, highlighting stable medical cost trends and improved provider alignment [22] - The company anticipates favorable macro tailwinds heading into 2026, with expected improvements in the rate environment communicated by CMS [22] - Management identified $120 million-$170 million in EBITDA expansion opportunities for 2026, positioning the company for meaningful profitability [23] Other Important Information - The company ended the quarter with $37.7 million in cash, maintaining a disciplined approach to working capital management [18] - The normalized medical cost trend has remained flat year-over-year, reflecting progress in clinical execution and cost management [17] Q&A Session Summary Question: What convinces the plans to cede margin in their M&A books? - Management indicated that payers are motivated by the investment made into their membership, particularly concerning high-risk patients and quality metrics [26] Question: Have you made an attempt to have the plans participate in a potential surplus? - Management confirmed that they take the risk from the payers, who receive their administrative margin, while the company operates on a percentage of premium [28] Question: Was the guidance reduction driven by a single payer or more broad-based? - The guidance reduction was primarily related to mid-year settlements coming in less than expected and was more broad-based than just one payer [36] Question: What was the prior period dollar amount in the third quarter? - The prior period amount net in the P&L was a $3 million decrement, with a total unfavorable impact of $24 million in Q3 due to mid-year true-ups [42][44] Question: What are the odds of another prior period adjustment in 2026? - Management expects a more consistent method of booking expenses and revenue moving forward, which should preclude significant normalization adjustments [46] Question: What was the PMPM revenue growth expectation in 2026? - Management anticipates about a 5% net improvement in premium across their markets, with further guidance on coding improvements expected in the next quarter [48]